April 24, 2025 11:47 PM

Latest:

DeSantis Caught Redirecting Medicaid Money to First Lady’s Foundation, Records Show
Campbell Takes Aim at Carney, Calls for ‘Clear-Eyed’ Review of Liberal Decade
The $40 Billion Gold COMEX Delivery ‘Error’ That Wasn’t An Error | Peter Krauth
Users’ Reach on X Dropped After Criticizing Musk, NYT Reports
Argentex Seeks Emergency Funding as Trump Tariffs Trigger Liquidity Crisis

the deep dive

Providing stock analysis for investors of the Canadian junior markets

Home
Latest
- Automotive
- Cannabis
- Commentary
- Full Analysis
- Gold
- Industrials
- Macro
- Oil
- Resources
- Technology
Resources
Energy
Technology
Coverage Companies
Verses AI
About
Contact Us

Goldman Sachs David Solomon Lollapalooza 2022

Latest

DeSantis Caught Redirecting Medicaid Money to First Lady’s Foundation, Records Show
Campbell Takes Aim at Carney, Calls for ‘Clear-Eyed’ Review of Liberal Decade
The $40 Billion Gold COMEX Delivery ‘Error’ That Wasn’t An Error | Peter Krauth
Users’ Reach on X Dropped After Criticizing Musk, NYT Reports
Argentex Seeks Emergency Funding as Trump Tariffs Trigger Liquidity Crisis
Trump Mulls Automotive Sector Relief from Certain Tariffs
Bessent Backpedals on China Tariff Cuts as Trump Strategy Falters
First Quantum Q1 2025 Net Cash Flow Drops By $440M As Net Loss Hits $23M

Video

The $40 Billion Gold COMEX Delivery ‘Error’ That Wasn’t An Error | Peter Krauth

April 24, 2025 1:37 PM JP Alegre 0

In this timely interview, Peter Krauth from SilverStockInvestor.com provides a comprehensive analysis of the current precious metals landscape amid increasing

WeightWatchers Prepares For Bankruptcy Protection As It Loses Ground to Ozempic
BMO Ends Partnership with Cathie Wood's ARK Investment, Shutters Funds
Trump Backtracks on China Tariffs After Economic Pressure Mounts
Trudeau’s Decision to Sell Canada’s Gold Reserves Has Now Cost Canada Over $149 million
Canada 2040: 9 In 10 Stay Trapped In The Class They’re Born Into

News

Biotech Latest News

Cardiol Sees First Patient Enrolled Under Phase III MAVERIC Clinical Trial

April 17, 2025 7:59 AM Jay Lutz 0

Cardiol Therapeutics (TSX: CRDL) has reached a major milestone with the announcement that the first patients have been enrolled into a phase III clinical trial for its lead drug candidate, CardiolRx™.

Rua Gold Hits 13.3 g/t Gold, 8.1% Antimony Over 1.25 Metres At Auld Creek

April 16, 2025 8:29 AM Jay Lutz 0

Canadian Copper To Begin Exploration At Murray Brook East

April 15, 2025 10:30 AM Jay Lutz 0

About

Welcome to The Deep Dive, where we focus on providing investors of Canadian junior stock markets the knowledge they need to make smart investment decisions. We take a closer look at all data relating to organizations listed on the CSE and the TSX Venture to create quality stock analysis for investors.

Not a recommendation to buy or sell securities. Always do additional research and consult a professional before purchasing a security.

Leave a ReplyCancel reply